|
InvivoGen
human tnf Human Tnf, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/recombinant+tnf-%CE%B1/pm42152018-124-13-23?v=InvivoGen Average 95 stars, based on 1 article reviews
human tnf - by Bioz Stars,
2026-08
95/100 stars
|
Buy from Supplier |
|
R&D Systems
nmol l tumor necrosis factor Nmol L Tumor Necrosis Factor, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/recombinant+tnf-%CE%B1/pmc13054578-103-43-49?v=R%26D+Systems Average 97 stars, based on 1 article reviews
nmol l tumor necrosis factor - by Bioz Stars,
2026-08
97/100 stars
|
Buy from Supplier |
|
Novoprotein
recombinant tnf α ![]() Recombinant Tnf α, supplied by Novoprotein, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/recombinant+tnf-%CE%B1/pmc13011060-390-8-11?v=Novoprotein Average 86 stars, based on 1 article reviews
recombinant tnf α - by Bioz Stars,
2026-08
86/100 stars
|
Buy from Supplier |
|
R&D Systems
human tnfα ![]() Human Tnfα, supplied by R&D Systems, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/recombinant+tnf-%CE%B1/pmc13068656-155-4-25?v=R%26D+Systems Average 97 stars, based on 1 article reviews
human tnfα - by Bioz Stars,
2026-08
97/100 stars
|
Buy from Supplier |
|
R&D Systems
tnf α ![]() Tnf α, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/recombinant+tnf-%CE%B1/pmc13129499-59-4-8?v=R%26D+Systems Average 93 stars, based on 1 article reviews
tnf α - by Bioz Stars,
2026-08
93/100 stars
|
Buy from Supplier |
|
InvivoGen
tnf α ![]() Tnf α, supplied by InvivoGen, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/recombinant+tnf-%CE%B1/bio_rxiv__64898__2026__04__23__720410-257-8-12?v=InvivoGen Average 95 stars, based on 1 article reviews
tnf α - by Bioz Stars,
2026-08
95/100 stars
|
Buy from Supplier |
|
R&D Systems
recombinant rat tnf alpha protein ![]() Recombinant Rat Tnf Alpha Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/recombinant+tnf-%CE%B1/pm42023950-330-10-14?v=R%26D+Systems Average 95 stars, based on 1 article reviews
recombinant rat tnf alpha protein - by Bioz Stars,
2026-08
95/100 stars
|
Buy from Supplier |
|
R&D Systems
recombinant mouse tnf alpha ![]() Recombinant Mouse Tnf Alpha, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/recombinant+tnf-%CE%B1/pm42013863-235-201-209?v=R%26D+Systems Average 96 stars, based on 1 article reviews
recombinant mouse tnf alpha - by Bioz Stars,
2026-08
96/100 stars
|
Buy from Supplier |
|
R&D Systems
recombinant mouse tumor necrosis factor α ![]() Recombinant Mouse Tumor Necrosis Factor α, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/recombinant+tnf-%CE%B1/pm42019888-56-8-26?v=R%26D+Systems Average 96 stars, based on 1 article reviews
recombinant mouse tumor necrosis factor α - by Bioz Stars,
2026-08
96/100 stars
|
Buy from Supplier |
Journal: Bioactive Materials
Article Title: Inhalable PD-L1-engineered hybrid cellular vesicles suppress excessive neutrophil activation and restore mitochondrial homeostasis to alleviate ischemia–reperfusion lung injury and pneumonia
doi: 10.1016/j.bioactmat.2026.03.024
Figure Lengend Snippet: Characterization of Res-PD-L1@nmEVs . (A) Schematic illustration of the Res-PD-L1@nmEVs synthesis procedure. (B-D) Representative transmission electron microscopy (TEM) images, dynamic light scattering (DLS) size distributions, and zeta potential measurements of nEVs, PD-L1@mEVs, PD-L1@nmEVs, and Res-PD-L1@nmEVs. (E) PD-L1 expression in PD-L1-overexpressing MSCs (OE-PD-L1) and negative control (NC) MSCs, and CD11b expression in HL60 cells before and after DMSO stimulation, as determined by Western blot. (F) Expression levels of neutrophil membrane markers (CD11b, CXCR2, RAGE, TLR2) and the exosomal marker CD63 in the four EV types. (G) Fluorescence co-localization images of DiO-labeled nEVs (green) and DiL-labeled PD-L1@mEVs (red) after fusion, demonstrating hybrid vesicle formation. (H) Size stability of Res-PD-L1@nmEVs stored at 4 °C and 37 °C for 7 days. (I-K) Binding and neutralization capacity of Res-PD-L1@nmEVs against inflammatory cytokines (TNF-α, IL-6, IL-1β) in vitro. ∗ vs. 0ug/ml; # vs. 100 μg/ml, p < 0.05, n = 5.
Article Snippet: These cells were then stimulated with 40 ng/mL
Techniques: Transmission Assay, Electron Microscopy, Zeta Potential Analyzer, Expressing, Negative Control, Western Blot, Membrane, Marker, Fluorescence, Labeling, Binding Assay, Neutralization, In Vitro
Journal: Bioactive Materials
Article Title: Inhalable PD-L1-engineered hybrid cellular vesicles suppress excessive neutrophil activation and restore mitochondrial homeostasis to alleviate ischemia–reperfusion lung injury and pneumonia
doi: 10.1016/j.bioactmat.2026.03.024
Figure Lengend Snippet: Res-PD-L1@nmEVs Attenuate Inflammation and Oxidative Damage in Lung Epithelial Cells In Vitro . (A-B) Flow cytometric analysis and quantification (B) of DiO-labeled Res-PD-L1@nmEVs uptake by BEAS-2B cells under H/R conditions after pretreatment with different endocytic inhibitors (chlorpromazine, chloroquine, and filipin) or incubation at 4 °C. (C) mRNA expression levels of IL-6, TNF-α, and IL-1β in BEAS-2B cells with or without H/R injury following pretreatment with Res, nEVs, PD-L1@mEVs, PD-L1@nmEVs, or Res-PD-L1@nmEVs. (D-E) Representative fluorescence images (D) and quantitative analysis (E) of cell proliferation assessed by BrdU incorporation (red; nuclei stained with DAPI, blue). Scale bar: 50 μm. (F-G) Apoptosis rates detected by flow cytometry (F) and flow cytometric analysis of Annexin V-positive BEAS-2B cells under the indicated conditions (G). (H–K) Fluorescence microscopy images and quantitative analysis of intracellular nitric oxide (NO, green) (H-I) and reactive oxygen species (ROS, red) (J-K). Scale bar: 100 μm. (L) Flow cytometry analysis of intracellular ROS levels. (M − O) Levels of malondialdehyde (MDA) (M), superoxide dismutase 2 (SOD2) activity (N), and glutathione (GSH) content (O) in cells. (P-Q) Cell migration ability evaluated by wound healing assay under different treatments. ∗ vs. Control; # vs. H/R; & vs. H/R + PD-L1@nmEVs, p < 0.05.
Article Snippet: These cells were then stimulated with 40 ng/mL
Techniques: In Vitro, Labeling, Incubation, Expressing, Fluorescence, BrdU Incorporation Assay, Staining, Flow Cytometry, Microscopy, Activity Assay, Migration, Wound Healing Assay, Control
Journal: Bioactive Materials
Article Title: Inhalable PD-L1-engineered hybrid cellular vesicles suppress excessive neutrophil activation and restore mitochondrial homeostasis to alleviate ischemia–reperfusion lung injury and pneumonia
doi: 10.1016/j.bioactmat.2026.03.024
Figure Lengend Snippet: Res-PD-L1@nmEVs Suppresses Neutrophil Activation HL60 cells were differentiated into neutrophil-like cells using DMSO and subsequently stimulated with TNF-α to induce activation under conditions simulating IRI. The effects of Res, nEVs, PD-L1@mEVs, PD-L1@nmEVs, and Res-PD-L1@nmEVs on neutrophil activation were evaluated. (A) Cell surface PD-1 expression analyzed by flow cytometry. (B) Representative immunofluorescence images of CD206 expression (red). Nuclei were stained with DAPI (blue). Scale bar: 50 μm. (C) Flow cytometric analysis of cell surface CD206 expression. (D) Flow cytometric analysis of cell surface CD95 expression. (E-G) Levels of myeloperoxidase (MPO) (E), neutrophil elastase (NE) (F), and MMP-9 (G) in neutrophil culture supernatants, measured by ELISA. (H-J) BEAS-2B cells were co-cultured with neutrophils in the presence or absence of TNF-α stimulation. Apoptosis levels (I) and migration capacity (J) of BEAS-2B cells were assessed under different treatment conditions. ∗ vs. Control; # vs. TNF-a; & vs. TNF-a+PD-L1@nmEVs, p < 0.05.
Article Snippet: These cells were then stimulated with 40 ng/mL
Techniques: Activation Assay, Expressing, Flow Cytometry, Immunofluorescence, Staining, Enzyme-linked Immunosorbent Assay, Cell Culture, Migration, Control
Journal: Bioactive Materials
Article Title: Inhalable PD-L1-engineered hybrid cellular vesicles suppress excessive neutrophil activation and restore mitochondrial homeostasis to alleviate ischemia–reperfusion lung injury and pneumonia
doi: 10.1016/j.bioactmat.2026.03.024
Figure Lengend Snippet: Res-PD-L1@nmEVs Effectively Attenuates MRSA-Induced Pneumonia (A-B) Rats with MRSA-induced pneumonia received three bronchial nebulization treatments over one week with different formulations (Res, nEVs, PD-L1@mEVs, PD-L1@nmEVs, or Res-PD-L1@nmEVs). (A) Representative H&E-stained lung sections and (B) corresponding lung injury scores are shown (n = 5). (C) TUNEL staining of lung tissues to assess apoptosis. (D) Representative micro-CT images of anesthetized rats. (E-G) Flow cytometric analysis of immune cell proportions in lung single-cell suspensions: CD8 + T cells (E), neutrophils (F), and classical monocytes (G). (H-J) Plasma levels of inflammatory cytokines IL-6 (H), IL-1β (I), and TNF-α (J) (n = 5). (K) Immunofluorescence staining of tight junction proteins Occludin (green) and ZO-1 (red) in lung tissues (nuclei stained with DAPI). Scale bar: 50 μm. (L-N) Pulmonary function parameters: lung compliance (L), airway resistance (M), and oxygenation index (N) (n = 4). ∗ vs. Sham; # vs. MRSA; & vs. MRSA + PD-L1@nmEVs, p < 0.05.
Article Snippet: These cells were then stimulated with 40 ng/mL
Techniques: Staining, TUNEL Assay, Micro-CT, Single Cell, Clinical Proteomics, Immunofluorescence
Journal: JID Innovations
Article Title: Development of a noninvasive device and method for measuring immune parameters in skin disease
doi: 10.1016/j.xjidi.2026.100456
Figure Lengend Snippet: Detection of inflammatory cytokines in skin wash of healthy volunteers and patients with AD and psoriasis. Cytokine concentrations were measured in skin wash fluid using Luminex assay. Inflammatory cytokines ( a ) IL-1β, ( b ) TNFα, ( c ) IL-18, and ( d ) IL-8. AD-related immune mediators ( e ) CCL13, ( f ) CCL18, ( g ) sIL-2R, and ( h ) IL-4. Psoriasis-associated immune mediators ( i ) IL-17A, ( j ) IL-23, ( k ) sTNFR1, and ( l ) IFNγ. Concentrations are depicted as mean ± SD, with individual data points shown. PS denotes psoriasis, NL denotes nonlesional, and L denotes lesional. ∗ P < .05, ∗∗ P < .01, and ∗∗∗ P < .001. AD, atopic dermatitis; HC, healthy control; sIL-2R, soluble IL-2R; sTNFR1, soluble TNFR1.
Article Snippet: E coli –derived recombinant
Techniques: Luminex, Control